Can Immunoadsorption Plasmapheresis Be Used as the First Choice Therapy for Neuroimmunological Disorders?
Identifieur interne : 002A59 ( Istex/Corpus ); précédent : 002A58; suivant : 002A60Can Immunoadsorption Plasmapheresis Be Used as the First Choice Therapy for Neuroimmunological Disorders?
Auteurs : Takemori Yamawaki ; Norihiro SuzukiSource :
- Therapeutic Apheresis [ 1091-6660 ] ; 1997-11.
English descriptors
- KwdEn :
Abstract
Abstract: The subjects were 31 patients in whom immunoadsorption plasmapheresis (IAPP) was performed as the first choice therapy for primary or recurrent neuroimmunological disorders. The clinical manifestations before and after IAPP and the use of corticosteroids were investigated in the present study. IAPP was clinically effective in all patients. The corticosteroids (CSs) administration was begun or CSs were increased after completion of IAPP in 11 patients. IAPP was performed as the first choice therapy, and favorable results were obtained in patients with Guillain‐Barré syndrome and Miller‐Fisher syndrome. IAPP alone was also effective in a patient with lupoid sclerosis. When IAPP was used alone in 2 patients with chronic inflammatory demyelinating polyradiculo‐neuropathy, it completely eliminated the clinical manifestations, but the symptoms recurred about 2 months later. Therefore, although IAPP could be performed as the first choice therapy for many neuroimmunological disorders, subsequent therapies should be carefully investigated.—
Url:
DOI: 10.1111/j.1744-9987.1997.tb00053.x
Links to Exploration step
ISTEX:4CF8EB74E603CE4F11B4BE1B97CE6E16A371254CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Can Immunoadsorption Plasmapheresis Be Used as the First Choice Therapy for Neuroimmunological Disorders?</title><author><name sortKey="Yamawaki, Takemori" sort="Yamawaki, Takemori" uniqKey="Yamawaki T" first="Takemori" last="Yamawaki">Takemori Yamawaki</name><affiliation><mods:affiliation>Department of Neurology, Mito Red Cross Hospital, Ibaraki, Japan</mods:affiliation></affiliation></author><author><name sortKey="Suzuki, Norihiro" sort="Suzuki, Norihiro" uniqKey="Suzuki N" first="Norihiro" last="Suzuki">Norihiro Suzuki</name><affiliation><mods:affiliation>Department of Neurology, Mito Red Cross Hospital, Ibaraki, Japan</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:4CF8EB74E603CE4F11B4BE1B97CE6E16A371254C</idno><date when="1997" year="1997">1997</date><idno type="doi">10.1111/j.1744-9987.1997.tb00053.x</idno><idno type="url">https://api.istex.fr/document/4CF8EB74E603CE4F11B4BE1B97CE6E16A371254C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002A59</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Can Immunoadsorption Plasmapheresis Be Used as the First Choice Therapy for Neuroimmunological Disorders?</title><author><name sortKey="Yamawaki, Takemori" sort="Yamawaki, Takemori" uniqKey="Yamawaki T" first="Takemori" last="Yamawaki">Takemori Yamawaki</name><affiliation><mods:affiliation>Department of Neurology, Mito Red Cross Hospital, Ibaraki, Japan</mods:affiliation></affiliation></author><author><name sortKey="Suzuki, Norihiro" sort="Suzuki, Norihiro" uniqKey="Suzuki N" first="Norihiro" last="Suzuki">Norihiro Suzuki</name><affiliation><mods:affiliation>Department of Neurology, Mito Red Cross Hospital, Ibaraki, Japan</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Therapeutic Apheresis</title><idno type="ISSN">1091-6660</idno><idno type="eISSN">1526-0968</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1997-11">1997-11</date><biblScope unit="volume">1</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="348">348</biblScope><biblScope unit="page" to="352">352</biblScope></imprint><idno type="ISSN">1091-6660</idno></series><idno type="istex">4CF8EB74E603CE4F11B4BE1B97CE6E16A371254C</idno><idno type="DOI">10.1111/j.1744-9987.1997.tb00053.x</idno><idno type="ArticleID">TAP348</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1091-6660</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Chronic inflammatory demyelinating polyradiculoneuropathy</term><term>Guillain‐Barré syndrome‐Miller‐Fisher syndrome</term><term>Immunoadsorbent column</term><term>Immunoadsorption plasmapheresis</term><term>Lupoid sclerosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: The subjects were 31 patients in whom immunoadsorption plasmapheresis (IAPP) was performed as the first choice therapy for primary or recurrent neuroimmunological disorders. The clinical manifestations before and after IAPP and the use of corticosteroids were investigated in the present study. IAPP was clinically effective in all patients. The corticosteroids (CSs) administration was begun or CSs were increased after completion of IAPP in 11 patients. IAPP was performed as the first choice therapy, and favorable results were obtained in patients with Guillain‐Barré syndrome and Miller‐Fisher syndrome. IAPP alone was also effective in a patient with lupoid sclerosis. When IAPP was used alone in 2 patients with chronic inflammatory demyelinating polyradiculo‐neuropathy, it completely eliminated the clinical manifestations, but the symptoms recurred about 2 months later. Therefore, although IAPP could be performed as the first choice therapy for many neuroimmunological disorders, subsequent therapies should be carefully investigated.—</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Takemori Yamawaki</name><affiliations><json:string>Department of Neurology, Mito Red Cross Hospital, Ibaraki, Japan</json:string></affiliations></json:item><json:item><name>Norihiro Suzuki</name><affiliations><json:string>Department of Neurology, Mito Red Cross Hospital, Ibaraki, Japan</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Immunoadsorption plasmapheresis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Immunoadsorbent column</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Guillain‐Barré syndrome‐Miller‐Fisher syndrome</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Lupoid sclerosis</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Chronic inflammatory demyelinating polyradiculoneuropathy</value></json:item></subject><articleId><json:string>TAP348</json:string></articleId><language><json:string>eng</json:string></language><abstract>Abstract: The subjects were 31 patients in whom immunoadsorption plasmapheresis (IAPP) was performed as the first choice therapy for primary or recurrent neuroimmunological disorders. The clinical manifestations before and after IAPP and the use of corticosteroids were investigated in the present study. IAPP was clinically effective in all patients. The corticosteroids (CSs) administration was begun or CSs were increased after completion of IAPP in 11 patients. IAPP was performed as the first choice therapy, and favorable results were obtained in patients with Guillain‐Barré syndrome and Miller‐Fisher syndrome. IAPP alone was also effective in a patient with lupoid sclerosis. When IAPP was used alone in 2 patients with chronic inflammatory demyelinating polyradiculo‐neuropathy, it completely eliminated the clinical manifestations, but the symptoms recurred about 2 months later. Therefore, although IAPP could be performed as the first choice therapy for many neuroimmunological disorders, subsequent therapies should be carefully investigated.—</abstract><qualityIndicators><score>4.336</score><pdfVersion>1.3</pdfVersion><pdfPageSize>614.399 x 793.68 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>5</keywordCount><abstractCharCount>1057</abstractCharCount><pdfWordCount>2584</pdfWordCount><pdfCharCount>16673</pdfCharCount><pdfPageCount>5</pdfPageCount><abstractWordCount>146</abstractWordCount></qualityIndicators><title>Can Immunoadsorption Plasmapheresis Be Used as the First Choice Therapy for Neuroimmunological Disorders?</title><genre><json:string>other</json:string></genre><host><volume>1</volume><publisherId><json:string>TAP</json:string></publisherId><pages><total>5</total><last>352</last><first>348</first></pages><issn><json:string>1091-6660</json:string></issn><issue>4</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1526-0968</json:string></eissn><title>Therapeutic Apheresis</title><doi><json:string>10.1111/(ISSN)1526-0968</json:string></doi></host><publicationDate>1997</publicationDate><copyrightDate>1997</copyrightDate><doi><json:string>10.1111/j.1744-9987.1997.tb00053.x</json:string></doi><id>4CF8EB74E603CE4F11B4BE1B97CE6E16A371254C</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/4CF8EB74E603CE4F11B4BE1B97CE6E16A371254C/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/4CF8EB74E603CE4F11B4BE1B97CE6E16A371254C/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/4CF8EB74E603CE4F11B4BE1B97CE6E16A371254C/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Can Immunoadsorption Plasmapheresis Be Used as the First Choice Therapy for Neuroimmunological Disorders?</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1997</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Can Immunoadsorption Plasmapheresis Be Used as the First Choice Therapy for Neuroimmunological Disorders?</title><author><persName><forename type="first">Takemori</forename><surname>Yamawaki</surname></persName><note type="correspondence"><p>Correspondence: Division of Cerebral Circulation Research, National Cardiovascular Center Research Institute, 5–7–1, Fujishirodai, Suita, Osaka 565, Japan.</p></note><affiliation>Department of Neurology, Mito Red Cross Hospital, Ibaraki, Japan</affiliation></author><author><persName><forename type="first">Norihiro</forename><surname>Suzuki</surname></persName><affiliation>Department of Neurology, Mito Red Cross Hospital, Ibaraki, Japan</affiliation></author></analytic><monogr><title level="j">Therapeutic Apheresis</title><idno type="pISSN">1091-6660</idno><idno type="eISSN">1526-0968</idno><idno type="DOI">10.1111/(ISSN)1526-0968</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1997-11"></date><biblScope unit="volume">1</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="348">348</biblScope><biblScope unit="page" to="352">352</biblScope></imprint></monogr><idno type="istex">4CF8EB74E603CE4F11B4BE1B97CE6E16A371254C</idno><idno type="DOI">10.1111/j.1744-9987.1997.tb00053.x</idno><idno type="ArticleID">TAP348</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1997</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Abstract: The subjects were 31 patients in whom immunoadsorption plasmapheresis (IAPP) was performed as the first choice therapy for primary or recurrent neuroimmunological disorders. The clinical manifestations before and after IAPP and the use of corticosteroids were investigated in the present study. IAPP was clinically effective in all patients. The corticosteroids (CSs) administration was begun or CSs were increased after completion of IAPP in 11 patients. IAPP was performed as the first choice therapy, and favorable results were obtained in patients with Guillain‐Barré syndrome and Miller‐Fisher syndrome. IAPP alone was also effective in a patient with lupoid sclerosis. When IAPP was used alone in 2 patients with chronic inflammatory demyelinating polyradiculo‐neuropathy, it completely eliminated the clinical manifestations, but the symptoms recurred about 2 months later. Therefore, although IAPP could be performed as the first choice therapy for many neuroimmunological disorders, subsequent therapies should be carefully investigated.—</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Immunoadsorption plasmapheresis</term></item><item><term>Immunoadsorbent column</term></item><item><term>Guillain‐Barré syndrome‐Miller‐Fisher syndrome</term></item><item><term>Lupoid sclerosis</term></item><item><term>Chronic inflammatory demyelinating polyradiculoneuropathy</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1997-11">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/4CF8EB74E603CE4F11B4BE1B97CE6E16A371254C/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1526-0968</doi><issn type="print">1091-6660</issn><issn type="electronic">1526-0968</issn><idGroup><id type="product" value="TAP"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="THERAPEUTIC APHERESIS">Therapeutic Apheresis</title></titleGroup></publicationMeta><publicationMeta level="part" position="11004"><doi origin="wiley">10.1111/tap.1997.1.issue-4</doi><numberingGroup><numbering type="journalVolume" number="1">1</numbering><numbering type="journalIssue" number="4">4</numbering></numberingGroup><coverDate startDate="1997-11">November 1997</coverDate></publicationMeta><publicationMeta level="unit" type="miscellaneous" position="0034800" status="forIssue"><doi origin="wiley">10.1111/j.1744-9987.1997.tb00053.x</doi><idGroup><id type="unit" value="TAP348"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="tocHeading1">Annual Meeting Presentations</title></titleGroup><eventGroup><event type="firstOnline" date="2007-11-14"></event><event type="publishedOnlineFinalForm" date="2007-11-14"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.6 mode:FullText source:HeaderRef result:HeaderRef" date="2010-04-21"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-10"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-11-04"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="348">348</numbering><numbering type="pageLast" number="352">352</numbering></numberingGroup><correspondenceTo>Division of Cerebral Circulation Research, National Cardiovascular Center Research Institute, 5–7–1, Fujishirodai, Suita, Osaka 565, Japan.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:TAP.TAP348.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Received August 1997</unparsedEditorialHistory><countGroup><count type="referenceTotal" number="18"></count><count type="linksCrossRef" number="3"></count></countGroup><titleGroup><title type="main">Can Immunoadsorption Plasmapheresis Be Used as the First Choice Therapy for Neuroimmunological Disorders?</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1" corresponding="yes"><personName><givenNames>Takemori</givenNames><familyName>Yamawaki</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a1"><personName><givenNames>Norihiro</givenNames><familyName>Suzuki</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="JP"><unparsedAffiliation>Department of Neurology, Mito Red Cross Hospital, Ibaraki, Japan</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en"><keyword xml:id="k1">Immunoadsorption plasmapheresis</keyword><keyword xml:id="k2">Immunoadsorbent column</keyword><keyword xml:id="k3">Guillain‐Barré syndrome‐Miller‐Fisher syndrome</keyword><keyword xml:id="k4">Lupoid sclerosis</keyword><keyword xml:id="k5">Chronic inflammatory demyelinating polyradiculoneuropathy</keyword></keywordGroup><abstractGroup><abstract type="main" xml:lang="en"><p><b>Abstract: </b> The subjects were 31 patients in whom immunoadsorption plasmapheresis (IAPP) was performed as the first choice therapy for primary or recurrent neuroimmunological disorders. The clinical manifestations before and after IAPP and the use of corticosteroids were investigated in the present study. IAPP was clinically effective in all patients. The corticosteroids (CSs) administration was begun or CSs were increased after completion of IAPP in 11 patients. IAPP was performed as the first choice therapy, and favorable results were obtained in patients with Guillain‐Barré syndrome and Miller‐Fisher syndrome. IAPP alone was also effective in a patient with lupoid sclerosis. When IAPP was used alone in 2 patients with chronic inflammatory demyelinating polyradiculo‐neuropathy, it completely eliminated the clinical manifestations, but the symptoms recurred about 2 months later. Therefore, although IAPP could be performed as the first choice therapy for many neuroimmunological disorders, subsequent therapies should be carefully investigated.—</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Can Immunoadsorption Plasmapheresis Be Used as the First Choice Therapy for Neuroimmunological Disorders?</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Can Immunoadsorption Plasmapheresis Be Used as the First Choice Therapy for Neuroimmunological Disorders?</title></titleInfo><name type="personal"><namePart type="given">Takemori</namePart><namePart type="family">Yamawaki</namePart><affiliation>Department of Neurology, Mito Red Cross Hospital, Ibaraki, Japan</affiliation><description>Correspondence: Division of Cerebral Circulation Research, National Cardiovascular Center Research Institute, 5–7–1, Fujishirodai, Suita, Osaka 565, Japan.</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Norihiro</namePart><namePart type="family">Suzuki</namePart><affiliation>Department of Neurology, Mito Red Cross Hospital, Ibaraki, Japan</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="other" displayLabel="miscellaneous"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1997-11</dateIssued><edition>Received August 1997</edition><copyrightDate encoding="w3cdtf">1997</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">18</extent></physicalDescription><abstract lang="en">Abstract: The subjects were 31 patients in whom immunoadsorption plasmapheresis (IAPP) was performed as the first choice therapy for primary or recurrent neuroimmunological disorders. The clinical manifestations before and after IAPP and the use of corticosteroids were investigated in the present study. IAPP was clinically effective in all patients. The corticosteroids (CSs) administration was begun or CSs were increased after completion of IAPP in 11 patients. IAPP was performed as the first choice therapy, and favorable results were obtained in patients with Guillain‐Barré syndrome and Miller‐Fisher syndrome. IAPP alone was also effective in a patient with lupoid sclerosis. When IAPP was used alone in 2 patients with chronic inflammatory demyelinating polyradiculo‐neuropathy, it completely eliminated the clinical manifestations, but the symptoms recurred about 2 months later. Therefore, although IAPP could be performed as the first choice therapy for many neuroimmunological disorders, subsequent therapies should be carefully investigated.—</abstract><subject lang="en"><genre>Keywords</genre><topic>Immunoadsorption plasmapheresis</topic><topic>Immunoadsorbent column</topic><topic>Guillain‐Barré syndrome‐Miller‐Fisher syndrome</topic><topic>Lupoid sclerosis</topic><topic>Chronic inflammatory demyelinating polyradiculoneuropathy</topic></subject><relatedItem type="host"><titleInfo><title>Therapeutic Apheresis</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">1091-6660</identifier><identifier type="eISSN">1526-0968</identifier><identifier type="DOI">10.1111/(ISSN)1526-0968</identifier><identifier type="PublisherID">TAP</identifier><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>1</number></detail><detail type="issue"><caption>no.</caption><number>4</number></detail><extent unit="pages"><start>348</start><end>352</end><total>5</total></extent></part></relatedItem><identifier type="istex">4CF8EB74E603CE4F11B4BE1B97CE6E16A371254C</identifier><identifier type="DOI">10.1111/j.1744-9987.1997.tb00053.x</identifier><identifier type="ArticleID">TAP348</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Informatique/explor/ScrumV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A59 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002A59 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Informatique
|area= ScrumV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:4CF8EB74E603CE4F11B4BE1B97CE6E16A371254C
|texte= Can Immunoadsorption Plasmapheresis Be Used as the First Choice Therapy for Neuroimmunological Disorders?
}}
| This area was generated with Dilib version V0.6.39. |  |